Biocon Limited (BSE code: 532523, NSE: BIOCON), a leader in global biopharmaceutical innovations, has announced a pivotal licensing and supply agreement with Brazil’s Biomm S.A., a specialty pharmaceutical company, to commercialize Semaglutide, a drug aimed at enhancing glycemic control in adults with type-2 diabetes. This exclusive partnership allows Biocon to handle the development, manufacturing, and […]
In a move marking a significant expansion in the biopharmaceutical sector, Eli Lilly and Company (Lilly) has successfully completed the acquisition of Versanis Bio, a clinical-stage biopharmaceutical player founded by Aditum Bio in 2021. This strategic acquisition sets the stage for Lilly to delve deeper into pioneering treatments for cardiometabolic diseases, including obesity. Central to […]
American pharma giant Eli Lilly and Company (Lilly) and Versanis Bio have announced a definitive agreement in which the former will acquire the privately-held clinical-stage biopharmaceutical company. Founded by Aditum Bio in 2021, Versanis Bio is focused on the development of new treatments for cardiometabolic diseases. The acquisition will see Versanis Bio’s leading asset, bimagrumab, […]